share_log

Transcode Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-3i, LP(9.9%),3i Management LLC(9.9%), etc.

Transcode Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-3i, LP(9.9%),3i Management LLC(9.9%), etc.

Transcode Therapeutics | SC 13G:超过5%持股股东披露文件-3i, LP(9.9%),3i Management LLC(9.9%)等
美股SEC公告 ·  07/26 16:09
Moomoo AI 已提取核心信息
On July 23, 2024, a Schedule 13G filing was made with the SEC by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively referred to as the Reporting Persons, indicating a significant stake in TransCode Therapeutics, Inc. The filing reveals that the Reporting Persons collectively hold 1,716,600 shares of TransCode Therapeutics' common stock, representing 9.9% of the company's shares outstanding as of July 24, 2024. The shares provide shared voting and dispositive power, which are managed by 3i Management LLC, with Maier Joshua Tarlow having the authority to vote and dispose of the shares. The principal business address for all Reporting Persons is in New York, NY. The filing asserts that the acquisition of the shares is not intended to change or influence the control of the issuer, and all parties have entered into a Joint Filing Agreement to file this and any subsequent amendments jointly.
On July 23, 2024, a Schedule 13G filing was made with the SEC by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively referred to as the Reporting Persons, indicating a significant stake in TransCode Therapeutics, Inc. The filing reveals that the Reporting Persons collectively hold 1,716,600 shares of TransCode Therapeutics' common stock, representing 9.9% of the company's shares outstanding as of July 24, 2024. The shares provide shared voting and dispositive power, which are managed by 3i Management LLC, with Maier Joshua Tarlow having the authority to vote and dispose of the shares. The principal business address for all Reporting Persons is in New York, NY. The filing asserts that the acquisition of the shares is not intended to change or influence the control of the issuer, and all parties have entered into a Joint Filing Agreement to file this and any subsequent amendments jointly.
2024年7月23日,由3i股票有限合伙公司、3i管理有限责任公司和Maier Joshua Tarlow共同提交了13G陈述申报书,这些人共同表示持有TransCode Therapeutics,Inc.的重要股权。申请书披露,申请人共持有TransCode Therapeutics普通股1716600股,占2024年7月24日公司流通股份的9.9%。这些股份提供共同的投票和处分权,由3i管理有限责任公司管理,Maier Joshua Tarlow有权投票和处理这些股份。所有报告人的主要营业地址均在纽约市。文件声明,收购这些股份并不打算改变或影响发行者的控制,并且所有各方已签署联合申报协议,共同提交本申报书及其任何后续修正案。
2024年7月23日,由3i股票有限合伙公司、3i管理有限责任公司和Maier Joshua Tarlow共同提交了13G陈述申报书,这些人共同表示持有TransCode Therapeutics,Inc.的重要股权。申请书披露,申请人共持有TransCode Therapeutics普通股1716600股,占2024年7月24日公司流通股份的9.9%。这些股份提供共同的投票和处分权,由3i管理有限责任公司管理,Maier Joshua Tarlow有权投票和处理这些股份。所有报告人的主要营业地址均在纽约市。文件声明,收购这些股份并不打算改变或影响发行者的控制,并且所有各方已签署联合申报协议,共同提交本申报书及其任何后续修正案。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息